title: Neoadjuvant chemotherapy with docetaxel and carboplatin followed by radical hysterectomy for stage IB2, IIA2, and IIB patients with non-squamous cell carcinoma of the uterine cervix.
abstract: BACKGROUND
  We conducted a phase II study to evaluate the efficacy of neoadjuvant chemotherapy with docetaxel and carboplatin followed by radical hysterectomy for patients with non-squamous cell carcinoma of the uterine cervix.
  
  
  METHODS
  Sixty-one patients with International Federation of Gynecology and Obstetrics stage IB2, IIA2, or IIB non-squamous cell carcinoma of the uterine cervix were enrolled. The patients were administered docetaxel at a dose of 60 mg/m2, followed by carboplatin at a dose based on an area under the curve of 6. The treatments were repeated every 21 days for one to three cycles. Fifty-two patients were eligible to evaluate the efficacy of neoadjuvant chemotherapy followed by radical hysterectomy. Adverse events were evaluated in 59 patients.
  
  
  RESULTS
  The response rate was 69 % (95 % CI, 57-82 %), with 5 patients achieving complete response, 31 partial response, 15 stable disease, and 1 progressive disease. Median follow-up duration was 1913 days with a range of 145-2632 days. Of 52 patients, 50 underwent radical hysterectomy after neoadjuvant chemotherapy. The 2-year overall survival rate was 81.8 % for stage IB2, 85.7 % for stage IIA2, and 92.6 % for stage IIB. The most frequent grade 3 and 4 hematological toxicity was neutropenia, with 43 patients experiencing grade 4 and 11 with grade 3. The nonhematological toxicities were mainly grade 1 or 2 in severity.
  
  
  CONCLUSIONS
  Neoadjuvant chemotherapy with docetaxel and carboplatin followed by radical hysterectomy may be a useful strategy for patients with non-squamous cell carcinoma of uterine cervix.
authors.affiliation: Department of Obstetrics and Gynecology, Tottori University School of Medicine, 36-1 Nishimachi, Yonago, Tottori, 683-8504, Japan. mshima12@med.tottori-u.ac.jp.
authors.forename: Muneaki
authors.initials: M
authors.lastname: Shimada
authors.affiliation: Department of Gynecology, Hyogo Cancer Center, 13-70 Kita-Oji, Akashi, Hyogo, 673-8558, Japan.
authors.forename: Shoji
authors.initials: S
authors.lastname: Nagao
authors.affiliation: Department of Gynecologic Oncology, Saitama Medical University International Medical Center, 1397-1 Yamane, Hidaka, Saitama, 350-1298, Japan.
authors.forename: Keiichi
authors.initials: K
authors.lastname: Fujiwara
authors.affiliation: Department of Gynecology, Cancer Institute Hospital, Koto-ku, Tokyo, 135-8550, Japan.
authors.forename: Nobuhiro
authors.initials: N
authors.lastname: Takeshima
authors.affiliation: Department of Gynecology, Cancer Institute Hospital, Koto-ku, Tokyo, 135-8550, Japan.
authors.forename: Ken
authors.initials: K
authors.lastname: Takizawa
authors.affiliation: Department of Obstetrics and Gynecology, Iwate Medical University, 19-1, Uchimaru, Morioka, Iwate, 020-8505, Japan.
authors.forename: Tadahiro
authors.initials: T
authors.lastname: Shoji
authors.affiliation: Department of Obstetrics and Gynecology, Iwate Medical University, 19-1, Uchimaru, Morioka, Iwate, 020-8505, Japan.
authors.forename: Toru
authors.initials: T
authors.lastname: Sugiyama
authors.affiliation: Department of Gynecology, Hyogo Cancer Center, 13-70 Kita-Oji, Akashi, Hyogo, 673-8558, Japan.
authors.forename: Satoshi
authors.initials: S
authors.lastname: Yamaguchi
authors.affiliation: Hyogo Prefectural Hospitals Agency, 5-10-1, Shimoyamate-dori, Kobe, Hyogo, 650-8567, Japan.
authors.forename: Ryuichiro
authors.initials: R
authors.lastname: Nishimura
authors.affiliation: Matsue City Hospital, 32-1 Noshiracho, Matsue, Shimane, 690-0045, Japan.
authors.forename: Junzo
authors.initials: J
authors.lastname: Kigawa
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects; D002277:Carcinoma / Q000473:pathology / Q000628:therapy; D000077143:Docetaxel; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007044:Hysterectomy / Q000379:methods*; D008875:Middle Aged; D020360:Neoadjuvant Therapy / Q000379:methods; D009367:Neoplasm Staging; D009503:Neutropenia / Q000175:diagnosis / Q000209:etiology; D011379:Prognosis; D015996:Survival Rate; D043823:Taxoids / Q000008:administration & dosage / Q000009:adverse effects; D016896:Treatment Outcome; D002583:Uterine Cervical Neoplasms / Q000473:pathology / Q000628:therapy
chemical_list: D000970:Antineoplastic Agents; D043823:Taxoids; D000077143:Docetaxel; D016190:Carboplatin
keywords: Neoadjuvant chemotherapy; Non-squamous cell carcinoma; Radical hysterectomy; Uterine cervical cancer